Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes

Kirsten L. White,a Nathan Osman,b Ernesto Cuadra-Foy,b Bluma G. Brenner,b Devleena Shivakumar,b Federico Campigotto,a Manuel Tsiang,a Philip A. Morganelli,a Nikolai Novikov,a Scott E. Lazerwith,a Haolun Jin,a Anita Niedziela-Majkaa

aGilead Sciences, Inc., Foster City, California, USA
bMcGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital and Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada

ABSTRACT The HIV integrase (IN) strand transfer inhibitor (INSTI) bictegravir (BIC) has a long dissociation half-life ($t_{1/2}$) from wild-type IN-DNA complexes: BIC 163 h > dolutegravir (DTG) 96 h > raltegravir (RAL) 10 h > elvitegravir (EVG) 3.3 h. In cells, BIC had more durable antiviral activity against wild-type HIV after drug washout than RAL or EVG. BIC also had a longer $t_{1/2}$ and maintained longer antiviral activity after drug washout than DTG with the clinically relevant resistance IN mutant G140S^1Q148H. Structural analyses indicate that BIC makes more contacts with the IN-DNA complex than DTG mainly via its bicyclic ring system, which may contribute to more prolonged residence time and resilience against many resistance mutations.

KEYWORDS HIV, bictegravir, dolutegravir, drug resistance, integrase, integrase inhibitors

HIV integrase (IN) is essential for viral replication, and the IN strand transfer inhibitors (INSTIs) bictegravir (BIC), dolutegravir (DTG), elvitegravir (EVG), and raltegravir (RAL) are potent antiretroviral drugs (1). All currently approved INSTIs share a pharmacophore consisting of a metal binding scaffold that effectively chelates the two active-site catalytic Mg^{2+} ions and prevents terminal viral nucleotide 3'-OH nucleophilic attack on the host DNA, thereby blocking integration (Table 1). These INSTIs show potent inhibition of HIV-1 replication in cells; however, there are distinct differences in their chemical structures, interaction with HIV-1 IN-DNA complexes, resistance profiles, and dissociation rates from complexes of IN bound to double-stranded DNA (IN-DNA complexes) (2–9). The apparent dissociation rate of DTG from IN-DNA complexes was previously shown to be longer than those of RAL and EVG and was predicted to correlate with potent antiretroviral activity and a higher genetic barrier to resistance, but direct comparison to BIC has not been investigated (2, 3). Here, the dissociation half-life ($t_{1/2}$) of BIC and other INSTIs were determined from wild-type (WT) and the clinically relevant G140S^1Q148H drug-resistant mutant IN bound to IN-DNA complexes in vitro. In cells, INSTI dissociation was measured as viral replication after drug washout. Molecular models of BIC and DTG bound to IN-DNA complexes based on recent cryo-electron microscopy (cryo-EM) structures provide structural insights into optimal binding geometry (2).

INSTI potency against WT HIV-1 has been well studied and, for the compounds described here, falls into the single-digit nanomole range (Table 1). BIC and DTG retain antiviral activity against many viral strains with INSTI resistance-associated mutations but show reduced activity against some complex mutants (4–9). The clinically relevant G140S^1Q148H confers high-level resistance to RAL and EVG, 4.3-fold reduced susceptibility to DTG, and 2.1-fold reduced susceptibility to BIC. To further understand the role of the benzyl tail and bicyclic ring system of BIC, we studied two related analogs:

Citation White KL, Osman N, Cuadra-Foy E, Brenner BG, Shivakumar D, Campigotto F, Tsiang M, Morganelli PA, Novikov N, Lazerwith SE, Jin H, Niedziela-Majka A. 2021. Long dissociation of bictegravir from HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 65:e02406-20. https://doi.org/10.1128/AAC.02406-20.

Copyright © 2021 White et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Kirsten L. White, kwhite@gilead.com.

Received 13 November 2020
Returned for modification 14 December 2020
Accepted 18 February 2021
Accepted manuscript posted online 1 March 2021
Published 19 April 2021
Table 1: Structure and antiviral activity of INSTIs in the MT-2 cell line

| INSTI  | Structure | Antiviral activity against HIV-1, EC_{50} (nM)\(^{b}\) (fold change) |
|--------|-----------|---------------------------------------------------------------|
|        |           | WT           | G140S+Q148H                                                   |
| BIC    | 1.5 ± 0.2 | 3.1 ± 0.8 (2.1)                                             |
| DTG    | 1.5 ± 0.2 | 6.5 ± 1.2 (4.3)                                             |
| RAL    | 9.4 ± 1.4 | 2,461 ± 323 (262)                                           |
| EVG    | 2.1 ± 0.9 | 868 ± 138 (413)                                             |
| Compound 1 | 1.4 ± 0.5 | 4.5 ± 1.8 (3.2)                                             |
| Compound 2 | 1.5 ± 0.5 | 11.1 ± 0.5 (7.4)                                            |

\(^{a}\)All compounds were synthesized at Gilead Sciences, Inc.
\(^{b}\)EC_{50} 50% effective concentration.

Compound 1 differs from BIC in that it contains a 2,4-difluorobenzyl group compared to a 2,4,6-trifluorobenzyl moiety in BIC, and compound 2 is the enantiomer of BIC (the bicyclic ring system is flipped in the opposite orientation). Compounds 1 and 2 showed more resistance to G140S+Q148H than BIC, and the orientation of the bicyclic ring system (compound 2 versus BIC) had a larger impact on mutant activity than the differences in the benzyl tail (compound 1 versus BIC).
To understand the reduced susceptibility of INSTIs to WT and G140S+Q148H IN, $t_{1/2}$ values were determined by a scintillation proximity assay as described in Hightower et al. (3). Once the maximal association of [3H]-INSTIs to IN-DNA complexes was achieved, INSTI dissociation was initiated by adding excess unlabeled INSTI, and the signal was measured for several days to weeks (Table 2). Data sets were analyzed using a single exponential decay analysis as previously published for INSTIs (3). For WT IN, BIC had a substantially longer $t_{1/2}$ (163 ± 31 h) than DTG (96 ± 29 h), RAL (10 ± 2 h), and EVG (3.3 ± 0.9 h). The DTG, RAL, and EVG $t_{1/2}$ values were comparable to those previously published using this methodology (3). Both compound 1 and compound 2 had $t_{1/2}$ values that were intermediate to BIC and DTG. This suggests that both presence and orientation of the bicyclic ring system and the trifluorobenzyl tail are important for longer WT $t_{1/2}$.

The dissociation of INSTIs from G140S+Q148H mutant IN-DNA complexes was also studied and showed that BIC had a $t_{1/2}$ of 5.7 ± 0.4 h compared to 34 ± 2 h for DTG. There was high-level resistance to RAL and EVG with G140S+Q148H mutants, resulting in an insufficient level of binding of these INSTIs to IN-DNA complexes for determination of dissociation kinetics. The $t_{1/2}$ values of compounds 1 and 2 from G140S+Q148H IN were also different from those of BIC and DTG. Compound 1 retained a longer $t_{1/2}$ for this mutant than DTG, whereas compound 2 had a shorter $t_{1/2}$, suggesting that both the presence and the specific orientation of the bicyclic ring system in BIC are more crucial than the benzyl tail modifications.

To probe the impact of the longer $t_{1/2}$ of BIC compared with other INSTIs in cells where all cellular intasome components are present, we used HIV-1 strain NL4.3 containing WT or G140S+Q148H to infect MT-2 cells and treated with BIC or other INSTIs. We then washed away the inhibitors 3 days postinfection and quantified the reverse transcriptase activity in the culture supernatant to evaluate viral growth as described in Jones et al. (22). INSTIs were tritiated by ViTrax (Placentia, CA) and had specific activities of 16.8 to 21.3 Ci/mmol. Streptavidin-coated scintillation proximity assay imaging beads (PerkinElmer, Boston, MA) were used, and oligonucleotides were obtained from Trilink (San Diego, CA), as described in Hightower et al. (3). The single exponential decay analysis was done as in Hightower et al., with the exception that we set background decay to 5%. The apparent dissociation rate constant was determined by curve fitting the competition binding phase after subtraction of 5% background to the 2-parameter single exponential decay equation: $y = M(e^{-kt} + b)$, where $M$ is the relative binding measured at the competition binding phase after subtraction of 5% background to the 2-parameter single exponential decay equation:

$$
 t_{1/2} = \frac{\ln(2)}{k_{\text{off}}}
$$

where $k_{\text{off}}$ is an apparent dissociation rate constant. The half-life, $t_{1/2}$, of the complex of INSTI bound to IN-DNA was calculated using the exact Wilcoxon rank sum test.

### TABLE 2 Dissociation half-lives and off rates of INSTIs from HIV-1 IN-DNA complexes

| INSTI          | Apparent $t_{1/2}$ (h) | $k_{\text{off}}$ (s$^{-1}$) ($\times$ 10$^{-6}$) | P value | Apparent $t_{1/2}$ (h) | $k_{\text{off}}$ (s$^{-1}$) ($\times$ 10$^{-6}$) | P value |
|----------------|------------------------|-----------------------------------------------|---------|------------------------|-----------------------------------------------|---------|
| BIC            | 163 ± 31               | 1.2 ± 0.3                                      | 0.0019  | 5.7 ± 0.4 (29)         | 34 ± 2 (0.04)                                 | 0.333   |
| DTG            | 96 ± 29 (71)           | 2.2 ± 0.7 (2.7 ± 0.4)                          | 0.0003  | 1.9 ± 0.2 (51) (3.3)   | 100 ± 9 (0.02) [58 ± 8]                       | 0.0019  |
| RAL            | 10 ± 2 (8.8)           | 21 ± 6 (22 ± 2)                                |         | ND (0.2)               | ND [1,130]                                    | ND      |
| EVG            | 3.3 ± 0.9 (2.7)        | 62 ± 16 (71 ± 4)                               | <0.0001 | ND (ND)                | ND [ND]                                       | ND      |
| Compound 1     | 155 ± 25               | 1.3 ± 0.2                                      | 0.594   | 4.8 ± 0.2 (32)         | 40 ± 2 (0.03)                                 | 0.2     |
| Compound 2     | 152 ± 35               | 1.3 ± 0.3                                      | 0.776   | 1.7 ± 0.2 (89)         | 114 ± 12 (0.01)                               | 0.2     |

*Values in square brackets are from reference 3. ND, not determined. The scintillation proximity assays for determination of HIV-1 INSTI and IN-DNA complex $t_{1/2}$ values were conducted according to the protocol defined in Hightower et al. (3) but measured using the HIDEQ Sense microplate reader (model 425-312, version 0.5.5.0; HIDEQ, Tirku, Finland) and were maintained at 37°C. Recombinant WT and G140S+Q148H mutant HIV-1 IN enzymes containing an N-terminal 6-histidine tag (6His-IN) were purified as described in Jones et al. (22). INSTIs were tritiated by ViTrax (Placentia, CA) and had specific activities of 16.8 to 21.3 Ci/mmol. Streptavidin-coated scintillation proximity assay imaging beads (PerkinElmer, Boston, MA) were used, and oligonucleotides were obtained from Trilink (San Diego, CA), as described in Hightower et al. (3). The single exponential decay analysis was done as in Hightower et al., with the exception that we set background decay to 5%. The apparent dissociation rate constant was determined by curve fitting the competition binding phase after subtraction of 5% background to the 2-parameter single exponential decay equation: $y = M(e^{-kt} + b)$, where $M$ is the relative binding measured at the first time point of a dissociation phase and $k_{\text{off}}$ is an apparent dissociation rate constant. The half-life, $t_{1/2}$, of the complex of INSTI bound to IN-DNA was calculated using the exact Wilcoxon rank sum test.

*Average ± standard deviation of 50% effective dose from 5 to 9 experiments for BIC, DTG, RAL, and EVG and 2 experiments for compounds 1 and 2.

*Comparison of $t_{1/2}$ values for INSTIs was made using the exact Wilcoxon rank sum test.
low replication under constant DTG pressure and significant viral replication 4 and 8 days after DTG washout. These data obtained in the more complex cell-based assay support the biochemical $t_{1/2}$ results. BIC maintained antiviral activity after washout for several days against WT and mutant HIV, which provides further evidence that long $t_{1/2}$s may prevent viral rebound and emergent resistance in vivo after missing doses of drug. These findings are consistent with the resistance profiles reported in Table 1.

To understand the longer $t_{1/2}$ of BIC from HIV-1 IN-DNA complexes compared with that of DTG, molecular models of the INSTIs using cryo-EM structures of BIC with simian immunodeficiency virus (SIV)mc32 IN (WT and G140S+Q148H mutant) or HIV-1 IN, viral DNA (vDNA) and BIC were generated (2). Previously solved X-ray structure of prototypic foamy virus (PFV)-IN (WT and G140S+Q148H mutant) or HIV-1 IN, viral DNA (vDNA) and BIC were generated (2). Previously solved X-ray structure of proto-

[FIG 1] Viral replication of WT (A) and G140S+Q148H (B) variants after treatment with DTG, BIC, EVG, and RAL following drug washout ($\Delta$) starting at washout day 0 (3 days postinfection). Drug levels corresponded to 20 times the 90% inhibitory concentration in this system (38 nM for BIC, 41.7 nM for DTG, 93.75 nM for RAL, and 24 nM for EVG). Replication was assessed by measuring RT activity in culture supernatant without and after drug washout. Bar graphs, mean ± SEM. Statistical significance of drug washout with drug control conditions were assessed by adjusted $P$ value with Tukey’s test: *, <0.05; ***, <0.001; and ****, <0.0001. For the washout experiments, BIC and EVG were synthesized at Gilead Sciences, Inc., DTG was purchased from Toronto Research Chemicals (ON, Canada), and RAL was provided by Merck, Inc.
INSTIs BIC and DTG are highly potent and have high genetic barriers to resistance. Emergent resistance to three-drug BIC- and DTG-based regimens has not occurred in clinical trials but has occurred in rare cases in clinical practice (13). EVG- and RAL-based regimens, which have lower genetic barriers to resistance, select for IN mutations at codons 140 and 148.

**FIG 2** Molecular models of BIC (A, gray), DTG (B, yellow), and overlap (C) bound to the HIV-1 IN active site. HIV-1 IN and vDNA are shown in blue-red-white and rainbow electrostatic surface representation, respectively. The two Mg$^{2+}$ ions are shown in magenta spheres. The bicyclic A-ring of BIC makes van der Waals contacts with the IN $\beta4-\alpha2$ loop (G118 shown for reference) and 3'-dA of the vDNA, filling up this region of the binding pocket efficiently and acting as additional anchoring points. DTG with its monocyclic ring and flipped stereochemistry makes partial contact with this region. Compound 2 (C, green) is a stereoisomer of BIC (gray) where the bicyclic ring points away from the 3'-dA vDNA. The optimal contacts of BIC with IN $\beta4-\alpha2$ loop and vDNA may be major contributors to anchoring the inhibitor in the pocket. Methodologies for the models are as follows. The INSTIs were docked to a homology model of WT and G140S+Q148H mutant HIV-1 IN based on cryo-EM structures (SIVrcm IN) (2) using Prime in Schrodinger Suite 2019-2 (Schrödinger, LLC, New York, NY) and a knowledge-based approach (23). The sequence alignment between SIVrcm IN (template) and HIV-1 IN (query) was optimized using ClustalW (24), yielding a sequence identity of 73%, a sequence similarity of 83%. The residues that were similar between the two sequences were retained while building the model. The side chains of the residues that were not part of the template were iteratively sampled using a coarse library of rotamers derived from known PDB structures until no clashes remained. The coordinates of all atoms not derived directly from the template itself were then minimized, producing the final refined model. BIC, DTG, and compound 2 were prepared with LigPrep with the metal binding states option using Schrodinger Suite 2019 (Schrödinger). INSTIs were docked using Glide XP docking protocol with expanded sampling method (25). Solvent molecules that coordinate to active site Mg$^{2+}$ ions were kept in place during docking. Top three docked poses for both the INSTIs were saved as an output.
REFERENCES

in the Department of Microbiology and Immunology, McGill University. Studies.

structural analysis, and Maureen Oliveira for performing RT assays. We thank Brian Schultz for input on analytical methods, Uli Schmitz for input on resistance barrier of BIC in the treatment of people living with HIV.

 Drug washout/release studies are consistent with a longer $t_{1/2}$ of BIC compared to DTG. Structural studies of the INSTI interactions with integrase intasomes (2, 12, 20, 21) and our models show that BIC forms a stable complex with HIV-1 IN bound to HIV-1 long-terminal-repeat DNA. The $t_{1/2}$ of BIC from HIV-1 IN-DNA complexes was longer than the $t_{1/2}$ of DTG, RAL, and EVG. The long $t_{1/2}$ of INSTIs with the integrase-DNA complex have been correlated with potent antiretroviral activity against WT HIV-1 integrase and a high barrier to resistance in vitro (3). BIC also dissociated more slowly than DTG from the resistant mutant G140S+Q148H IN-DNA complex, which is consistent with the greater in vitro activity of BIC than of other INSTIs against this mutant (2–9). Long $t_{1/2}$ and more optimal binding-site complementarity of the INSTI into its binding site may also translate into more favorable resistance profiles when the INSTI may tolerate small perturbations in the pocket induced by amino acid mutations. The impact of a longer BIC $t_{1/2}$ due to more optimal interactions with HIV-1 IN and vDNA may lead to greater tolerance of binding-site perturbations by drug resistance mutations and forgiveness of missed doses. These in vitro data further our understanding of the high efficacy and resistance barrier of BIC in the treatment of people living with HIV.

ACKNOWLEDGMENTS

We acknowledge Kendra Hightower for the well-described protocol and Peter Cherepanov for sharing structural information before publication and for insights into the structural differences between DTG and BIC in the SIV IN-DNA complex. In addition, we thank Brian Schultz for input on analytical methods, Uli Schmitz for input on structural analysis, and Maureen Oliveira for performing RT assays.

We thank Merck for the donation of RAL to the Brenner lab for the drug washout studies.

The cell-based experiments performed by N.O. were components of his Ph.D. studies in the Department of Microbiology and Immunology, McGill University.

REFERENCES

1. Lesbats P, Engelman AN, Cherepanov P. 2016. Retroviral DNA integration. Chem Rev 116:12730–12757. https://doi.org/10.1021/acs.chemrev.6b00125.

2. Cook NJ, Li W, Berta D, Badouei M, Ballandras-Colas A, Nans A, Kotecha A, Rosta E, Engelman AN, Cherepanov P. 2020. Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science 367:806–810. https://doi.org/10.1126/science.aaq4919.

3. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase ant mutant G140S

4. Tsang M, Jones GS, Goldsmith L, Mulato A, Hansen D, Kan E, Tsai L, Ram RA, Stepan G, Stray KM, Nedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazewitz SE, White KL, Jin H. 2016. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 60:7086–7097. https://doi.org/10.1128/AAC.01474-16.

5. Santoro MM, Fornabaio C, Malena M, Galli L, Poli A, Menozzi M, Zazzi M, White KL, Castagna A, Prestigio Study Group. 2020. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. Int J Antimicrob Agents 56:106027. https://doi.org/10.1016/j.ijantimicag.2020.106027.

6. Smith SJ, Zhao XZ, Burke TR, Jr, Hughes SH. 2018. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology 15:37. https://doi.org/10.1186/s12977-018-0420-7.

7. Smith RA, Raugi DN, Wu VH, Zavala CG, Song J, Diallo KM, Seydi M, Gottlieb GS, Sall F, Mouhamadou Baina D, Faye K, Cisse S, Pierre Sy M, Diaw B, Ndiaye O, Faye B, Diop NA, Diop AB, Diome MF, Malomar JJ, Sall EI, Cisse O, Tamba IT, Faye D, Diatta JP, Bakhour R, Jacques Francois S, Juliette G, Dieye T, Hawes S, Benzekri N, Lin J, Nixon R, Burhen P, Chang M, Coombs R, Mullins J, Sow PS, Kiviat N, University of Washington-Dakar

May 2021 Volume 65 Issue 5 e02406-20 aac.asm.org 6
15. Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Brenner BG, Montreal Primary HIV (PHI) Cohort Study Group. 2018. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 15:56. https://doi.org/10.1186/s12977-018-0440-3

10. Osman N, Mesplede T, Oliveira M, Ibanescu RI, Anstett K, Mesplede T, Routy JP, Robbins MA, Wainberg MA. 2018. Durable suppression of HIV-1 with resistance mutations to integrase strand transfer inhibitors cabotegravir and bictegravir in HIV-1 non-B subtypes. AIDS 32:1773–1780. https://doi.org/10.1097/QAD.000000000001903.

11. Quan Y, Brenner BG, Essex M, Kurimura T, Wainberg MA. 2003. Mutants of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 19:743–753. https://doi.org/10.1089/088922203769232548.

12. Passos DO, Li M, Jóźwik IK, Zhao XZ, Santos-Martins D, Yang R, Smith SJ, Jean Y, Forli S, Hughes SH, Burke TR, Craige R, Lyumkis D. 2020. Structural basis for strand-transfer inhibitor binding to HIV intasomes. Science 367:810–814. https://doi.org/10.1126/science.aay8015.

13. Cevik M, Orkin C, Sax PE. 2020. Emergent resistance to dolutegravir among INSTI-naive patients on first-line or second-line antiretroviral therapy: a review of published cases. Open Forum Infect Dis 7:ofaa202. https://doi.org/10.1093/ofid/ofaa202.

14. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Cruwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Liu H, Rockstroh JK, Girard PM, Antinori A, Antinori A, Ortiz R, Clarke AE, Hugn CC, Jin H, Kim CU, Wright M, Gelezianus R, Tsiang M. 2009. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 53:1994–2003. https://doi.org/10.1128/AAC.00984-08.

15. Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettaochi C, Brinson C, Phillibert P, Lombaard J, St Clair M, Cruwels H, Ford SL, Patel P, Chounta V, Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Wyman S. 2020. Long-acting cabotegravir and rilpivirine for maintenance therapy for HIV-1 infection. N Engl J Med 382:1124–1135. https://doi.org/10.1056/NEJMoa1909512.

16. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 203:1204–1214. https://doi.org/10.1093/infdis/jir025.

17. Blanco JL, Marxchin AG, Katlama C, Martinez E. 2018. Dolutegravir resistance mutations: lessons from monotherapy studies. Curr Opin Infect Dis 31:237–245. https://doi.org/10.1097/QCO.0000000000000453.

18. Cahn P, Madero JS, Arribas JR, Antinori A, Orz Z, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Underwood M, Papp A, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B. Durable efficacy of dolutegravir (DTD) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection—3-year results from the Gemini studies, poster 018. HIV Glasgow, 5 to 8 October 2020.

19. Takwo BQ, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. 2018. ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)–infected participants with HIV-1 RNA <500000 copies/mL. Clin Infect Dis 66:1689–1697. https://doi.org/10.1093/cid/cix1083.

20. Jóźwik IK, Passos DO, Lyumkis D. 2020. Structural biology of HIV integrase strand transfer inhibitors. Trends Pharmacol Sci 41:611–626. https://doi.org/10.1016/j.tips.2020.06.003.

21. Patani GA, LaVoie EJ. 1996. Bioisosterism: a rational approach in drug design. Chem Rev 96:3176–3177. https://doi.org/10.1021/cr950066q.

22. Jones GS, Yu F, Zynalnataedan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Gelezianus R, Tsiang M. 2009. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 53:1994–2003. https://doi.org/10.1128/AAC.00984-08.

23. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA. 2004. A hierarchical approach to all-atom protein loop prediction. Proteins 55:351–367. https://doi.org/10.1002/prot.10613.

24. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680. https://doi.org/10.1093/nar/22.22.4673.

25. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky AE. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. https://doi.org/10.1021/jm0306430.